The latest update is out from Summit Therapeutics (SMMT).
Summit Therapeutics Inc. shared promising results from the HARMONi-A trial at the ASCO Annual Meeting, highlighting the effectiveness of ivonescimab plus chemotherapy in treating non-small cell lung cancer with EGFR variant. This Phase III study, sponsored and analyzed by Akeso in China, has not only garnered attention at ASCO but also led to the authorization of the treatment in China, with its findings published in the prestigious Journal of the American Medical Association.
For detailed information about SMMT stock, go to TipRanks’ Stock Analysis page.
